$293 Million is the total value of Foresite Capital Management IV, LLC's 17 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 38.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Buy | Insmed Incorporated | $42,584,000 | +5.1% | 1,800,587 | +0.1% | 14.52% | -13.6% |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd. | $33,639,000 | +53.4% | 851,200 | 0.0% | 11.47% | +26.1% | |
| IMMU | Buy | Immunomedics, Inc. | $29,151,000 | +85.9% | 1,231,543 | +14.7% | 9.94% | +52.8% |
| MYOK | Buy | Myokardia, Inc. | $28,090,000 | +46.9% | 565,755 | +44.3% | 9.58% | +20.7% |
| CBAY | Sell | CymaBay Therapeutics, Inc. | $27,154,000 | -1.0% | 2,023,369 | -4.2% | 9.26% | -18.6% |
| OPTN | Buy | OptiNose, Inc. | $25,981,000 | +168.3% | 928,545 | +92.0% | 8.86% | +120.6% |
| RYTM | Buy | Rhythm Pharmaceuticals, Inc. | $22,567,000 | +467.0% | 721,903 | +261.0% | 7.69% | +366.2% |
| ABUS | Buy | Arbutus Biopharma Corporation | $19,358,000 | +160.7% | 2,651,825 | +78.5% | 6.60% | +114.3% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $17,989,000 | -42.1% | 270,424 | -43.1% | 6.13% | -52.4% |
| ALDR | Buy | Alder BioPharmaceuticals, Inc. | $17,869,000 | +69.3% | 1,130,919 | +36.1% | 6.09% | +39.2% |
| ACRS | Buy | Aclaris Therapeutics, Inc. | $10,575,000 | +40.5% | 529,551 | +23.3% | 3.60% | +15.5% |
| Sell | Alder BioPharmaceuticals, Inc.put | $5,530,000 | -30.0% | 350,000 | -22.2% | 1.88% | -42.4% | |
| EIDX | New | Eidos Therapeutics, Inc. | $4,985,000 | – | 245,082 | +100.0% | 1.70% | – |
| RCUS | Sell | Arcus Biosciences, Inc. | $3,611,000 | -64.0% | 295,000 | -54.6% | 1.23% | -70.4% |
| TCDA | New | Tricida, Inc. | $2,243,000 | – | 75,000 | +100.0% | 0.76% | – |
| KNSA | New | Kiniksa Pharmaceuticals, Ltd. | $1,639,000 | – | 94,477 | +100.0% | 0.56% | – |
| QURE | Sell | uniQure N.V. | $403,000 | -96.9% | 10,650 | -98.1% | 0.14% | -97.5% |
| SLDB | Exit | Solid Biosciences Inc. | $0 | – | -140,332 | -100.0% | -0.44% | – |
| RARX | Exit | Ra Pharmaceuticals, Inc. | $0 | – | -450,000 | -100.0% | -0.99% | – |
| Exit | Myokardia, Inc.put | $0 | – | -100,000 | -100.0% | -2.03% | – | |
| Exit | Insmed Incorporatedput | $0 | – | -300,000 | -100.0% | -2.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.